Table 1.

Comparison of commercially available hybrid closed-loop systems.

	CamAPS FX	MiniMed 670G System	Tandem Control-IQ
Regulatory approvals
Age licensed for	1 year +	7 years +	14 years +
Countries licensed in	Europe	USA & Europe	USA & Europe
Location of algorithm	App-based	Pump-integrated	Pump-integrated
Compatible with factory calibrated CGM	Yes – Dexcom G6	No – regular finger-prick calibrations required	Yes – Dexcom G6
Insulins licensed for	Rapid- and ultra-rapid acting	Rapid-acting	Rapid-acting
System features
Parameters required for system setup	TDD, weight	TDD, weight, ICR, ISF, basal rates	TDD, weight, ICR, ISF, basal rates
Adaptive learning	Overall, diurnal, meals	Overall	None
Target type	Treat-to-target: default 5.8mmol/L	Treat-to-target: 6.7mmol/L	Treat-to-range: 6.2–8.9mmol/L
Adjustable glucose target	Personalised target 4.4 – 11mmol/L; Personalised time-blocks	Temporary target option of 8.3mmol/L	Overnight target range 6.1–6.7mmol/L (Sleep Activity) Exercise target range 7.8–8.9mmol/L
Active insulin time	Automatically adjusted based on adaptive learning	Personalised active insulin time of 2–8 hours	Factory-set at 5 hours; not adjustable
Automated correction bolus	No	No	Yes, when glucose is predicted to be >10mmol/L and not in Sleep Activity
Automode suspension	No	Yes	No
Automated data upload to cloud	Diasend	No	No
User features
Phone-based bolusing	Yes	No	No
Activity mode	Yes	Yes	Yes
Boost mode	Yes	No	No
Remote glucose monitoring	Yes – SMS alerts	No	Yes – live Followers

[CGM – continuous glucose monitoring; TDD – total daily dose; ICR – insulin-to-carbohydrate ratio; ISF – insulin sensitivity factor; Boost mode in CamAPS FX is user-initiated and intensifies algorithm-driven insulin delivery for use during periods of high glucose e.g. minor illness, pre-menstrual, growth hormone pulses etc.]